The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder. It causes high cholesterol levels that lead to heart disease, heart attack, or stroke. Additionally, HeFH is one form of Familial Hypercholesterolemia (FH). The major factor driving the demand for the heterozygous familial hypercholesterolemia drug is the increasing prevalence of familial hypercholesterolemia across the globe. 

According to Medline Plus, familial hypercholesterolemia affects an estimated 1 in 200 to 1 in 250 people in most countries. Additionally, it is the most common inherited condition affecting the heart and blood vessels. Furthermore, the condition occurs more frequently in certain populations that include Afrikaners in South Africa, Lebanese, and Tunisians. Hence, the increasing prevalence of familial hypercholesterolemia is driving the demand for heterozygous familial hypercholesterolemia drugs for treatment which in turn is driving the growth of the market.

Some major players in the market include Sanofi SA, Amgen Inc., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, Amgen announced the approval of  Repatha (evolocumab) from the US Food and Drug Administration (FDA). It is used as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C)-lowering therapies for the treatment of heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 10 years and older.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Sanofi SA, Amgen Inc., and Novartis International AG, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Heterozygous Familial Hypercholesterolemia Drug Market Report by Segment

By Type

• Gemcabene Calcium

• MGL-3196

• ST-103

• Others

By Application 

• Hospital

• Medical Center

• Clinics

• Others

Global Heterozygous Familial Hypercholesterolemia Drug Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa